Novartis has stuck on a second deal with Orionis Biosciences, this time handing $40 million upfront to the molecular glue biotech to work on “challenging therapeutic targets across multiple disease areas.”
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
Novartis has stuck on a second deal with Orionis Biosciences, this time handing $40 million upfront to the molecular glue biotech to work on “challenging therapeutic targets across multiple disease areas.”